Special Issue

Multi-Omics Approaches to Tumor Antigen Discovery and Immunotherapy Target Identification

Message from the Guest Editors

Identifying clinically actionable tumor antigens and immunotherapy targets requires integrated approaches that bridge genomic, transcriptomic, proteomic, and immunological landscapes. Recent advances in multi-omics technologies have revolutionized our ability to discover novel cancer-associated antigens, understand immune recognition mechanisms, and identify molecular regulators of anti-tumor immunity. This special issue focuses on innovative multi-omics strategies for tumor antigen discovery, validating immunogenic targets, and identifying molecular mechanisms that regulate therapeutic responses in cancer. We welcome contributions exploring integrated omics pipelines for antigen discovery, phosphoproteomic and spatial transcriptomic approaches to dissecting tumor immunity, novel cancer-associated antigens and their immune recognition, molecular targets enhancing immune responses, and translational studies bridging discovery to immunotherapy development.

Guest Editors

Dr. Esen Yonca Bassoy
Department of Immunology, Mayo Clinic, Phoenix, AZ 85259, USA
Dr. Parvin Zamani
Department of Immunology, Mayo Clinic, Phoenix, AZ 85259, USA

Deadline for manuscript submissions

31 July 2026

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/si/261499

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers

MDPI

Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/journal/cancers

MDPI

About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)